Pathway Genomics and Salud Interactiva announce partnership to bring advanced clinical genetic testing to millions in Mexico

SAN DIEGO, CA ----Pathway Genomics and Salud Interactiva, a company backed by Sinca Inbursa, today announced a partnership that will make Pathway’s wide range of clinical genetic testing with advanced Artificial Intelligence analysis available to millions of Salud Interactiva’s users in Mexico. Salud Interactiva, a leading third party administrator offering health services in 3 countries, has a network of over 6 million users and associations comprised of insurance companies, private clinics (e.g. Bio Clinique), and other corporate partners.  

Pathway Genomics to Present at the 2017 UBS Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Pathway Genomics, an innovative commercial-stage genomics company, announced today that Dr. Michael Nova, Chief Innovation Officer, and Kamal Adawi, Chief Financial Officer, will present at the 2017 UBS Global Healthcare Conference. This event will be held at the Grand Hyatt in New York City on Monday, May 22nd through May 24th. Pathway’s presentation will take place Monday, May 22, 2017 at 3:00 p.m. EDT. The presentation will be available on Pathway.com.  

Pathway Genomics to participate in NASDAQ Fit Week

NASDAQ-2017-PR-Background-image

San Diego, CA - (BUSINESS WIRE) – January 2, 2017 --- Pathway Genomics, an innovative commercial-stage genomics company, announced today that they will be participating in the 7th annual NASDAQ Fit Week. PathwayFit®, their test that assesses 80 genetic markers to help personalize and optimize diet, nutrition, metabolic health and exercise regimes, will be featured at Fit Week. As part of the event, Pathway will be offering PathwayFit® for a special price of $199 during the month of January and will also kick off the “This Is My Pathway” video contest to help create awareness about making informed, proactive lifestyle decisions.

“Pathway is proud of their partnership with NASDAQ and pleased to be a part of this event again in 2017,” said Jim Plante, Founder & CEO. “We are focused on providing genetic testing to help people better understand their propensity for risk so they are able to personalize their healthcare and make positive behavior changes that lead to improved overall health.”

To learn more about PathwayFit, visit http://www.pathway.com/fit-199 and to enter the This Is My Pathway video contest for a chance to win the $1000 Grand Prize visit http://www.pathway.com/thisismypathway.

About Pathway Genomics

Founded in 2008, Pathway Genomics offers digital healthcare and genetic testing. Based in San Diego, CA our CLIA and CAP accredited clinical laboratory provides physicians and their patients in 40+ countries with actionable and accurate precision healthcare information to improve health and wellness. The company’s program with IBM Watson is a smartphone app that merges artificial intelligence and deep learning with personal genetic information. The app provides users with personalized health and wellness information based on the individual’s health history.

Pathway believes in the power of “genetics first” to help make proactive, informed decisions about health and lifestyle. Our physician-ordered tests include assays for diet and weight loss, circulating tumor DNA (liquid biopsy), hereditary cancer, pharmacogenomics and carrier screening. For more about Pathway Genomics, visit www.pathway.com and follow us on Facebook, LinkedIn and Twitter.

PATHWAY GENOMICS CONTACTS:

 

Media, Press & Marketing:

Blythe Lawton, Senior Director, Marketing

858.568.7002

blythe.lawton@pathway.com

 

Investor Relations:

Kamal Adawi, Chief Financial Officer

858.900.3002

Kamal.Adawi@pathway.com

Pathway Genomics CIO, Dr. Michael Nova, to Present at the 2017 CES Digital Health Conference

2017-CES-Digital-Health-Conference

San Diego, CA - (BUSINESS WIRE) – December 28, 2016 ---Pathway Genomics, a cutting-edge commercial-stage genomics company, announced today that Dr. Michael Nova, Chief Innovation Officer, will present and be a panelist at the 2017 CES Digital Health Conference in Las Vegas, Nevada. The Conference will be held January 4-8, 2017 at The Venetian Hotel.

Dr. Nova will present at the following sessions:

Consumer Health Data Goes to the Doctor on Wednesday January 4th from 11:30am-12:30pm in LVCC North Hall, N261
The Audacity of Precision Medicine: Bona Fide, Fearless, Unchained on Friday January 6th from 1-1:30pm in Lando 4303, Level 4
I am delighted to participate at CES Digital Health to discuss how Pathways OME Artificial Intelligence App and IBM Watson program can dramatically impact healthcare and the internet of things (IoT), said Dr. Nova. Healthcare is indeed now. Personalized and Audacious and due to AI, Big Data and genetics, is dramatically changing for the user and physician.

In other news, Pathway is also running a special New Year promotion during the month of January where patients can go online and order PathwayFit test for only $199 through the Pathway Online Physician network with code MYPATHWAY.

About Pathway Genomics

Founded in 2008, Pathway Genomics offers digital healthcare and genetic testing. Based in San Diego, CA our CLIA and CAP accredited clinical laboratory provides physicians and their patients in 40+ countries with actionable and accurate precision healthcare information to improve health and wellness. The companys program with IBM Watson is a smartphone app that merges artificial intelligence and deep learning with personal genetic information. The app provides users with personalized health and wellness information based on the individuals health history.

Pathway believes in the power of ?genetics first to help make proactive, informed decisions about health and lifestyle. Our physician-ordered tests include assays for diet and weight loss, circulating tumor DNA (liquid biopsy), hereditary cancer, pharmacogenomics and carrier screening. For more about Pathway Genomics, visit www.pathway.com and follow us on Facebook, LinkedIn and Twitter.
Contacts

Pathway Genomics
Blythe Lawton, Senior Director, Marketing
858.568.7002
blythe.lawton@pathway.com

Pathway Genomics to Present & Exhibit at The 24th Annual World Congress on Anti-Aging Medicine

2016_A4M NOVA

San Diego, CA - (BUSINESS WIRE) – December 8, 2016 ---Pathway Genomics, an innovative commercial-stage genomics company, announced today that Dr. Michael Nova, Chief Innovation Officer, will present at the 24th Annual World Congress on Anti-Aging Medicine in Las Vegas, Nevada. Dr. Nova will present on Nutritional Genetics and Epigenetics in Diabetes and Obesity Management on Friday December 9th at 2:55pm in the Veronese Room (2503-4/2403-4) at the Venetian Hotel. Additionally, Pathway will be exhibiting at the conference in booth 3098.

“Pathway is pleased to be a part of this cutting-edge conference,” said Jim Plante,Founder & CEO. “We strongly believe in preventative medicine and are proud to partner with A4M to promote disease prevention and lifestyle management that enables today’s health practitioners for sustained success in the management of their patients.”

About Pathway Genomics

Founded in 2008, Pathway Genomics offers digital healthcare and genetic testing. Based in San Diego, CA our CLIA and CAP accredited clinical laboratory provides physicians and their patients in 40+ countries with actionable and accurate precision healthcare information to improve health and wellness. The company’s program with IBM Watson is a smartphone app that merges artificial intelligence and deep learning with personal genetic information. The app provides users with personalized health and wellness information based on the individual’s health history.

Pathway believes in the power of “genetics first” to help make proactive, informed decisions about health and lifestyle. Our physician-ordered tests include assays for diet and weight loss, circulating tumor DNA (liquid biopsy), hereditary cancer, pharmacogenomics and carrier screening. For more about Pathway Genomics, visit www.pathway.com and follow us on Facebook, LinkedIn and Twitter.

CONTACT

Blythe Lawton, Senior Director, Marketing
858.568.7002
blythe.lawton@pathway.com

Pathway Genomics’ Chief Financial Officer, Kamal Adawi, to present at the 28th Annual Piper Jaffray Healthcare Conference

2016_Jaffrey_web_banner2

San Diego, CA - (BUSINESS WIRE) – November 28, 2016 --- Pathway Genomics, an innovative commercial-stage genomics company, announced today that Kamal Adawi, Chief Financial Officer, will present at the 28th Annual Piper Jaffray Healthcare Conference. This conference will be held at The Lotte New York Palace in New York City on November 29th and 30th and the presentation will be made available on Pathway.com and Pathway’s social media.

“Pathway is honored to be a part of this important conference,” said Jim Plante, Founder & CEO. “We believe that proactively sharing healthcare industry knowledge helps us all gain a broader perspective that ultimately allows us to help more patients.”

About Pathway Genomics

Founded in 2008, Pathway Genomics offers digital healthcare and genetic testing. Based in San Diego, CA our CLIA and CAP accredited clinical laboratory provides physicians and their patients in 40+ countries with actionable and accurate precision healthcare information to improve health and wellness. The company’s program with IBM Watson is a smartphone app that merges artificial intelligence and deep learning with personal genetic information. The app provides users with personalized health and wellness information based on the individual’s health history.

Pathway believes in the power of “genetics first” to help make proactive, informed decisions about health and lifestyle. Our physician-ordered tests include assays for diet and weight loss, circulating tumor DNA (liquid biopsy), hereditary cancer, pharmacogenomics and carrier screening. For more about Pathway Genomics, visit www.pathway.com and follow us on Facebook, LinkedIn and Twitter.

 

CONTACT

Investor Relations
Kamal Adawi, Chief Financial Officer
858.900.3002
kamal.adawi@pathway.com

Pathway Genomics’ Chief Financial Officer, Kamal Adawi to present at Canaccord Genuity Medical Technology & Diagnostics Forum

Canaccord genuity pr Kamal Adawi

SAN DIEGO--(BUSINESS WIRE)--Pathway Genomics, an innovative commercial-stage genomics company, announced today that Kamal Adawi, Chief Financial Officer, will present at the 2016 Canaccord Genuity Medical Technology & Diagnostics Forum, which will be held at the Westin Grand Central Hotel in New York City on Thursday, November 17, 2016.

About Pathway Genomics

Founded in 2008, Pathway Genomics offers digital healthcare and genetic testing. Based in San Diego, CA our CLIA and CAP accredited clinical laboratory provides physicians and their patients in 40+ countries with actionable and accurate precision healthcare information to improve health and wellness. The company’s program with IBM Watson is a smartphone app that merges artificial intelligence and deep learning with personal genetic information. The app provides users with personalized health and wellness information based on the individual’s health history.

Pathway believes in the power of “genetics first” to help make proactive, informed decisions about health and lifestyle. Our physician-ordered tests include assays for diet and weight loss, circulating tumor DNA (liquid biopsy), hereditary cancer, pharmacogenomics and carrier screening. For more about Pathway Genomics, visit www.pathway.com and follow us on Facebook, LinkedIn and Twitter.

Contacts
Pathway Genomics
Investor Relations
Kamal Adawi, Chief Financial Officer
858.900.3002
kamal.adawi@pathway.com

G-TAC – M3 (a Sony Company) and Pathway Genomics Partner to Market CancerIntercept™, BRCATrue® and Fitness Genetic Tests in Japan

G-TAC_PathwayGenomics-partnership_Header

TOKYO -- (BUSINESS WIRE) -- G-TAC Co., Ltd. and M3, Inc. (an associated company of SONY) announced a strategic business partnership with Pathway Genomics to market fourteen tests including CancerIntercept™, BRCATrue®, PathwayFit®, SkinFit™ and other genetic tests through G-TAC’s genomics network of over 20,000 physicians in Japan.

Genomics and Personalized Medicine

The cost of genome sequencing is rapidly decreasing and has enabled us to utilize the technology for actual clinical purpose. For example, in 2003 when the Human Genome Project was completed, the cost was three billion USD and it took thirteen years to analyze the data. Today the cost would be 1,000 USD and data analysis would be complete within a day. With this dramatic advancement in genome sequencing technology, there are more clinical efforts to offer accurate, individualized assessment of inherited disease risk to provide personalized health management and preventative medicine.

Genomics in the US: One Step Ahead of Japan

One of the countries that leads this growing movement is the United States. Advanced hospitals and clinics have applied personalized medicine such as genetic cancer testing, pharmacogenomics and preventative treatments that are genetically personalized for disease risk and health and wellness. This, combined with President Obama’s “Precision Medicine Initiative,” has led to increased research and focus among public and private sectors.

Pathway Genomics: A Pioneer of Genetic Testing in the US

The genomics industry in the US is composed of a number of revolutionary companies, one of the most advanced of which is Pathway Genomics. Since their founding in 2008, the company has developed a broad scope of specialized genetic testing services to assess cancer risk, cardiac health, inherited diseases, nutrition and exercise response and medication response. Currently Pathway provides genetic testing services in over 40 countries. They are also committed to developing innovative services such as a health app powered by IBM Watson’s artificial intelligence and a cutting-edge liquid biopsy test that may detect, identify and monitor most major cancers through the use of a simple blood test.

M3, G-TAC and Pathway: Genomics Partnering for Success

From July 20, 2016, M3 and G-TAC will begin promoting fourteen of Pathway’s genetic tests through “m3.com,” which is the largest physician network in Japan, and “g-tac.me,” which is a platform of genomics and personalized medicine for consumers and physicians. Additionally in an effort to support patients wherever they reside, G-TAC will provide tele-medicine counseling with licensed genetic experts who will follow up on test results.

Comments

Jim Plante, Pathway Genomics CEO:

“It is a great honor to be affiliated with G-TAC and their network of 20,000 leading physicians and 100 hospitals. Our organizations share a deep mutual commitment to ensuring that patients can access and benefit from the most advanced scientific treatments available in the world today.”

Shotaro Uematsu, G-TAC CEO/ President of Genome Business Group at M3:

“It is a pleasure to announce our partnership with Pathway Genomics, who leads this field with innovative technologies such as their smartphone genome app with artificial intelligence and liquid biopsy testing. With thorough localization in Japan, we will be able to provide convenient access for physicians and consumers to the world’s leading genomic and personalized medicine diagnostics.“

About G-TAC Co., Ltd & M3

G-TAC’s corporate mission is to advance the development of genomics and personalized medicine. With the concept of “Know and create yourself through genomics,” G-TAC provides informed, actionable information for both physicians and consumers. M3 Inc. was established in September 2000 under the service name of So-net, with Sony Communications Network Corporation, a supplier of network-related services, as the largest stockholder. M3 was founded with the goal of changing the world of medicine through making full use of the power of the Internet.

By utilizing the “m3.com” platform, G-TAC has access the largest physician portal in Japan. They are able to reach 80,000 unique users and a network of 20,000 physicians, or “G-TAC members,” who have established interest in genomic medicine. Additionally, G-TAC provides tele-medicine counseling through “G-TAC (https://g-tac.me),” with licensed genetic experts who follow-up on test results with patients who are connected to over 100 hospitals and clinics all over Japan.

For more information about M3 visit http://corporate.m3.com/en. For more information about G-TAC, visit https://g-tac.co.jp.

Contacts

Pathway Genomics
Blythe Lawton, 858-568-7002
or
G-TAC Co., Ltd.
Shotaro Uematsu, +81-3-6679-2255
s-uematsu@g-tac.co.jp
or
Tomohiro Takano
info@g-tac.co.jp

Pathway Genomics Provides Updates for CancerIntercept™ Detect Clinical Program

Pathway Genomics Provides Updates for CancerIntercept™ Detect Clinical Program

Three Clinical Investigations Now Enrolling with the Initiation of New Study in Thyroid Cancer Detection
Two Abstracts Published in 2016 ASCO Annual Meeting Proceedings

SAN DIEGO May 26, 2016  – Pathway Genomics today provided an update on the clinical development program for its liquid biopsy, CancerIntercept™ Detect, a non-invasive screening test for detection of mutations that have been associated with cancer. Pathway Genomics researchers have initiated a clinical trial for the detection of thyroid cancer – the company’s third ongoing study for the technology. The company also announced the publication of two abstracts in the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting Proceedings. “The initiation of the thyroid study is an important step in our clinical development program for CancerIntercept and will help increase our understanding of its potential as a biomarker for the early detection of thyroid cancer,” said Glenn Braunstein, M.D., chief medical officer of Pathway Genomics. “We are in the process of initiating additional disease specific studies for early cancer detection in high risk patients, including a study in lung cancer, and will present and publish the data in the appropriate forums.”  

Pathway Genomics Debuts First Genomic Wellness App Powered by IBM Watson

Pathway Genomics Debuts First Genomic Wellness App Powered by IBM Watson

Alpha Release of OME™ Incorporates Genetics and other Data for Personalized Wellness Recommendations

LAS VEGAS 7 January 2016  Pathway Genomics and IBM (NYSE: IBM) today unveiled at the Digital Health Summit at CES 2016 the closed-alpha release of Pathway Genomics OME™ app, powered by Watson. The Pathway Genomics OME app merges cognitive computing and deep learning with precision medicine and genetics to enable Pathway Genomics to provide consumers with personalized wellness information. This alpha version of the app incorporates information from Pathway’s “FIT” Test — a wellness-based diet, exercise, and metabolism report compiled with information from the users unique genetic traits, as well as their health habits, data from GPS and wearable health monitors in addition to information from the users Apple HealthKit. Future versions of Pathway’s OME will enable users to opt-in to include electronic health records, insurance information, and additional datasets that will enable OME to provide precise and actionable wellness recommendations.